Trials / Completed
CompletedNCT04946305
A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
A Post Marketing Surveillance on Lutathera® (Lutetium (177Lu) Oxodotreotide, 177Lu-DOTA0-Tyr3-Octreotate) in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) in Korea
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 89 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Lutathera | Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled. |
Timeline
- Start date
- 2022-05-10
- Primary completion
- 2024-07-08
- Completion
- 2024-07-08
- First posted
- 2021-06-30
- Last updated
- 2024-08-09
Locations
6 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04946305. Inclusion in this directory is not an endorsement.